BMEZ:NYE-BlackRock Health Sciences Trust II (USD)

COMMON STOCK | |

Last Closing

USD 15.58

Change

-0.15 (-0.95)%

Market Cap

USD 1.65B

Volume

0.28M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Address: 50 Hudson Yards, New York, NY, United States, 10001

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
TBB AT&T Inc

-0.13 (-0.55%)

USD 146.86B
PRS Prudential Financial Inc

-0.15 (-0.61%)

USD 44.13B
ALL-PB The Allstate Corporation

-0.04 (-0.15%)

USD 33.62B
SOJC Southern Co

+0.02 (+0.08%)

USD 23.86B
AIZN Assurant Inc

-0.10 (-0.45%)

USD 9.38B
RZB Reinsurance Group of America I..

+0.03 (+0.12%)

USD 8.80B
PCG-PA Pacific Gas and Electric Compa..

+0.25 (+1.02%)

USD 6.63B
PCG-PB Pacific Gas and Electric Compa..

N/A

USD 5.89B
UNMA Unum Group

N/A

USD 5.72B
PCG-PD Pacific Gas and Electric Compa..

N/A

USD 5.31B

ETFs Containing BMEZ

YYY Amplify High Income ETF 2.98 % 0.50 %

-0.08 (-0.66%)

USD 0.55B
PCEF Invesco CEF Income Compos.. 0.00 % 0.50 %

-0.02 (-0.66%)

USD 0.81B

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.35% N/A N/A 49% F
Dividend Return 9.11% N/A N/A 94% A
Total Return 15.46% N/A N/A 60% D-
Trailing 12 Months  
Capital Gain 14.81% N/A N/A 53% F
Dividend Return 10.52% N/A N/A 92% A
Total Return 25.33% N/A N/A 63% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.04% N/A N/A 10% F
Dividend Return -0.11% N/A N/A 21% F
Total Return 5.93% N/A N/A 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 24.54% N/A N/A 45% F
Risk Adjusted Return -0.46% N/A N/A 22% F
Market Capitalization 1.65B N/A N/A 64% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike